Is ImmunoGen Inc. (IMGN) A Risky Investment?

ImmunoGen Inc. (NASDAQ:IMGN) trading with a subtraction of -$0.05 to $5.99 on Friday, a downside of -0.91 percent. An average of 1,054,119 shares of common stock have been traded in the last five days. There was a gain of $0.09 in the past week. The last 20 days have seen an average of 1,342,535 shares traded, while the 50-day average volume stands at 1,344,202.

IMGN stock has increased by 3.78% in the last month. The company shares reached their 1-month lowest point of $5.41 on 09/16/21. With the stock rallying to its 52-week high on 02/12/21, shares of the company touched a low of $4.26 and a high of $10.88 in 52 weeks. In spite of this, the price is down -44.99% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

281 days have passed since ImmunoGen Inc. (IMGN) last reported insider trading activity. FOSTER DAVID G, who is V.P.-Fin., Prin. Acctg. Off., most recently acquired $11,052 shares at $6.38 per share on Dec 31.

Valuation Metrics

ImmunoGen Inc. (IMGN) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 31.97 for the sector. This means investors are optimistic about the stock’s future prospects. The stock’s beta is 1.32. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 8.82, the price-to-book (PB) ratio at 17.76.

The quick ratio of ImmunoGen Inc. for the three months ended June 29 was 2.30, and the current ratio was 2.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.02 for the quarter ending June 29. ImmunoGen Inc.’s EBITDA margin for the year ending June 29 is -14.20%, while its operating margin for the same period stands at -26.70%. Its gross profit as reported stood at $154.68 million compared to revenue of $132.3 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, ImmunoGen Inc.’s return on assets was -17.80%. For the broader industry, ROE averaged -68.79 over the past year.

Earnings Surprise

The analyst consensus anticipated ImmunoGen Inc.’s latest quarter earnings to come in at -$0.18 per share, but it turned out to be -$0.15, a 16.70% surprise. For the quarter, EBITDA amounted to -$26.83 million. Shareholders own equity worth $201.62 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at ImmunoGen Inc. (IMGN) price momentum. RSI 9-day as of the close on 07 October was 58.63%, suggesting the stock is Neutral, with historical volatility in this time frame at 34.86%.

As of today, IMGN’s price is $5.95 +1.44% or $0.09 from its 5-day moving average. IMGN is currently trading +4.62% higher than its 20-day SMA and -11.84% lower than its 100-day SMA. However, the stock’s current price level is +6.11% above the SMA50 and -14.36% below the SMA200.

The stochastic %K and %D were 74.79% and 71.44%, respectively, and the average true range (ATR) was 0.22. With the 14-day stochastic at 76.72% and the average true range at 0.23, the RSI (14) stands at 55.86%. The stock has reached 0.13 on the 9-day MACD Oscillator while the 14-day reading was at 0.09.

Analyst Ratings

The consensus rating for ImmunoGen Inc. (IMGN) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell IMGN, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.

What is IMGN’s price target for the next 12 months?

Analysts predict a range of price targets between $6.00 and $17.00, with a median target of $9.00. Taking a look at these predictions, the average price target given by analysts for ImmunoGen Inc. (IMGN) stock is $9.93.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam